Table 1 Characteristics and clinical data of the study subjects

Age, median (IQR)

45.5(36.5–51)

44 (36–49)

59 (45–59)

0.05

Gender

 Female, n (%)

11 (36.6%)

7 (28%)

4 (80%)

0.04

 Male, n (%)

19 (63.3%)

18 (72%)

1 (20%)

0.04

Smoking, n (%)

9 (30%)

9 (36%)

0 (0%)

ns

BMI (kg/m2), median (IQR)

31.9(28.7–34)

31.8 (28–35)

32(31.1–32)

ns

Comorbidities

 DM2, n (%)

5 (16.6%)

4 (16%)

1 (20%)

ns

 Hypertension, n (%)

1 (3%)

1 (4%)

0 (0%)

ns

 Respiratory disease, n (%)

3 (10%)

3 (12%)

0 (0%)

ns

 Obesity

26 (86.6%)

21 (84%)

5 (100%)

ns

Prior vaccination

0

0

0

Days after symptoms onset, median (IQR)

7 (6–9.7)

7 (7–10)

4 (4–7)

ns

Antibiotic treatment, n (%)

23 (76.6%)

20 (80%)

3 (60%)

ns

 Cephalosporins

19 (63.3%)

16 (64%)

2 (40%)

ns

 Macrolides

4 (13.3%)

3 (12%)

1 (20%)

ns

 Penicillin

3 (6.6%)

2 (8%)

1 (20%)

ns

 Quilonones

3 (6.6%)

3 (12%)

0 (0%)

ns

Days at ICU, median (IQR)

17.5 (10–29.2)

14 (10–30)

21 (12–27)

ns

Symptoms

 Cough, n (%)

21 (70%)

16 (64%)

5 (100%)

ns

 Fever, n (%)

21 (70%)

18 (72%)

3 (60%)

ns

 Dyspnea, n (%)

21 (70%)

18 (72%)

3 (60%)

ns

 Headache, n (%)

15 (50%)

11 (44%)

4 (80%)

ns

 Myalgia, n (%)

17 (56.6%)

14 (56%)

3 (60%)

ns

 Arthralgia, n (%)

17 (56.6%)

14 (56%)

3 (60%)

ns

 Rhinorrhea, n (%)

9 (30%)

8 (32%)

1 (20%)

ns

 Chest pain, n (%)

7 (23.3%)

4 (16%)

3 (60%)

0.05

 Diarrhea, n (%)

4 (13.3%)

3 (12%)

1 (20%)

ns

 Cyanosis, n (%)

12 (40%)

8 (32%)

4 (80%)

ns

Severity scores

 APACHE II

11 (8.2–12.7)

11 (8–11)

17(14–17)

0.001

 SOFA

4 (3–5)

4 (3–5)

5(2–6)

ns

 SAPS II

28 (13–38)

26 (13–36)

38(10–39)

ns